000156826 001__ 156826
000156826 005__ 20240229123117.0
000156826 0247_ $$2doi$$a10.3390/cancers12051335
000156826 0247_ $$2pmid$$apmid:32456181
000156826 0247_ $$2pmc$$apmc:PMC7281312
000156826 0247_ $$2altmetric$$aaltmetric:82930281
000156826 037__ $$aDKFZ-2020-01143
000156826 041__ $$aeng
000156826 082__ $$a610
000156826 1001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b0$$eFirst author$$udkfz
000156826 245__ $$aCan 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
000156826 260__ $$aBasel$$bMDPI$$c2020
000156826 3367_ $$2DRIVER$$aarticle
000156826 3367_ $$2DataCite$$aOutput Types/Journal article
000156826 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600768782_15869
000156826 3367_ $$2BibTeX$$aARTICLE
000156826 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156826 3367_ $$00$$2EndNote$$aJournal Article
000156826 500__ $$a#EA:E060#LA:E060#
000156826 520__ $$aThere is an unmet need for positron emission tomography (PET) radiotracers that can image bone disease in multiple myeloma (MM) in a more sensitive and specific way than the widely used 18F-fluorodeoxyglucose (18F-FDG). Sodium fluoride (18F-NaF) is a highly sensitive tracer of bone reconstruction, evolving as an important imaging agent for the assessment of malignant bone diseases. We attempted to investigate for the first time the prognostic significance of 18F-NaF PET/CT in newly diagnosed, symptomatic MM patients planned for autologous stem cell transplantation (ASCT). Forty-seven patients underwent dynamic and static PET/CT with 18F-NaF before treatment. After correlation with the respective findings on CT and 18F-FDG PET/CT that served as reference, the 18F-NaF PET findings were compared with established factors of high-risk disease, like cytogenetic abnormalities as well as bone marrow plasma cell infiltration rate. Furthermore, the impact of 18F-NaF PET/CT on progression-free survival (PFS) was analyzed. Correlation analysis revealed a moderate, significant correlation of the 18F-NaF parameters SUVaverage and K1 in reference tissue with bone marrow plasma cell infiltration rate. However, no significant correlation was observed regarding all other 18F-NaF PET parameters. Survival analysis revealed that patients with a pathologic 18F-NaF PET/CT have a shorter PFS (median = 36.2 months) than those with a physiologic scan (median = 55.6 months) (p = 0.02). Nevertheless, no quantitative 18F-NaF parameter could be shown to adversely affect PFS. In contrast, the respective analysis for quantitative dynamic 18F-FDG PET/CT revealed that the parameters SUVmax, fractional blood volume (VB), k3 and influx from reference tissue as well as SUVaverage from MM lesions had a significant negative impact on patient survival. The herein presented findings highlight the rather limited role of 18F-NaF PET/CT as a single PET approach in MM.
000156826 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000156826 588__ $$aDataset connected to CrossRef, PubMed,
000156826 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b1$$udkfz
000156826 7001_ $$aMerz, Maximilian$$b2
000156826 7001_ $$aJauch, Anna$$b3
000156826 7001_ $$aRaab, Marc-Steffen$$b4
000156826 7001_ $$aGoldschmidt, Hartmut$$b5
000156826 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b6$$eLast author$$udkfz
000156826 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers12051335$$gVol. 12, no. 5, p. 1335 -$$n5$$p1335$$tCancers$$v12$$x2072-6694$$y2020
000156826 909CO $$ooai:inrepo02.dkfz.de:156826$$pVDB
000156826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000156826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000156826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000156826 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000156826 9141_ $$y2020
000156826 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2019-12-21
000156826 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2019-12-21
000156826 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2019-12-21
000156826 9202_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000156826 9200_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000156826 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000156826 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000156826 980__ $$ajournal
000156826 980__ $$aVDB
000156826 980__ $$aI:(DE-He78)E060-20160331
000156826 980__ $$aI:(DE-He78)C060-20160331
000156826 980__ $$aUNRESTRICTED